207 related articles for article (PubMed ID: 26023680)
1. Tumor talk: understanding the conversation between the tumor and its microenvironment.
Whipple CA
Cancer Cell Microenviron; 2015 Apr; 2(2):e773. PubMed ID: 26023680
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.
Jolly LA; Novitskiy S; Owens P; Massoll N; Cheng N; Fang W; Moses HL; Franco AT
Cancer Res; 2016 Apr; 76(7):1804-13. PubMed ID: 26818109
[TBL] [Abstract][Full Text] [Related]
3. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
7. The tumor microenvironment: shaping cancer progression and treatment response.
Desai SA; Patel VP; Bhosle KP; Nagare SD; Thombare KC
J Chemother; 2024 Jan; ():1-30. PubMed ID: 38179655
[TBL] [Abstract][Full Text] [Related]
8. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
9. The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy.
Wo YJ; Gan ASP; Lim X; Tay ISY; Lim S; Lim JCT; Yeong JPS
Cells; 2019 Dec; 9(1):. PubMed ID: 31861847
[TBL] [Abstract][Full Text] [Related]
10. [Tumor microenvironment: promising therapeutic target].
Kawasaki Y; Akiyama T
Nihon Rinsho; 2015 Aug; 73(8):1283-7. PubMed ID: 26281679
[TBL] [Abstract][Full Text] [Related]
11. Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C; Mendes R; Baptista PV; Fernandes AR
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781344
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment.
Xiong Y; McDonald LT; Russell DL; Kelly RR; Wilson KR; Mehrotra M; Soloff AC; LaRue AC
World J Stem Cells; 2015 Mar; 7(2):253-65. PubMed ID: 25815113
[TBL] [Abstract][Full Text] [Related]
13. Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.
Zhou L; Yang K; Andl T; Wickett RR; Zhang Y
J Cancer; 2015; 6(8):717-26. PubMed ID: 26185533
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment pathways: Cross regulation in breast cancer metastasis.
Malla RR; Kiran P
Genes Dis; 2022 Mar; 9(2):310-324. PubMed ID: 35224148
[TBL] [Abstract][Full Text] [Related]
15.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
16. [Progress of anti-tumor study based on BRAF].
Yan GR; Xu ZJ; Wang HY; Zhu WL
Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
18. Targeting the microenvironment in solid tumors.
Belli C; Trapani D; Viale G; D'Amico P; Duso BA; Della Vigna P; Orsi F; Curigliano G
Cancer Treat Rev; 2018 Apr; 65():22-32. PubMed ID: 29502037
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
Muntimadugu E; Kommineni N; Khan W
Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
[TBL] [Abstract][Full Text] [Related]
20. Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.
Menon DR; Schaider H
J Invest Dermatol; 2015 Dec; 135(12):2923-2925. PubMed ID: 26569587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
